Lange K, Gysler A, Bader M, Kleuser B, Korting H C, Schäfer-Korting M
Institut für Pharmazie II, Abteilung Pharmakologie und Toxikologie Freie Universität Berlin.
Pharm Res. 1997 Dec;14(12):1744-9. doi: 10.1023/a:1012183914011.
Pharmacodynamic characterization of topical glucocorticoids as prednicarbate (PC), its metabolites prednisolone 17-ethylcarbonate (PEC) and prednisolone (PD), betamethasone 17-valerate (BMV), betamethasone (BM) and desoximetasone (DM) by evaluating their effects on epidermal and dermal cells. Synopsis of pharmacokinetic and pharmacodynamic studies, possibly explaining the improved benefit-risk ratio of prednicarbate.
Isolated foreskin keratinocytes were used to investigate the influence on epidermal inflammatory processes, dermal fibroblasts of the same origin to study antiproliferative activities of glucocorticoids. Interleukins were measured by ELISA-assay, the influence on II-1 alpha-production also on mRNA-level by RNAse protection assay. Proliferation was assessed by 3H thymidine incorporation and biodegradation by HPLC/UV-absorption. Cell viability was controlled by MTT assay.
In keratinocytes, inflammation was induced by TNF alpha, resulting in an increased II-1 alpha synthesis. This cytokine was particularly suppressed by PC and BMV, whereas PEC, PD, DM and BM were less potent (p < or = 0.05). Since, however, the double ester PC is rapidly degraded in keratinocytes, a RNAse-protection assay of II-1 alpha mRNA was performed allowing short incubation times and thus minimizing biodegradation effects. In agreement with the previous experiment, the antiinflammatory potency of native PC was confirmed. In fibroblasts, II-1 alpha and II-6 synthesis indicate proliferation and inflammation respectively. Whereas PC inhibited II-1 alpha and II-6 production in fibroblasts to a minor extent only, it was strongly reduced by the conventional glucocorticoids and PEC (p < or = 0.05). The minor unwanted effect of PC on fibroblasts was also reflected by its low influence on cell proliferation as assayed by 3H thymidine incorporation. More pronounced antiproliferative features were observed with BM, PEC and especially BMV.
Correlating antiphlogistic effects in keratinocytes (suppression of II-1 alpha) with antiproliferative effects in fibroblasts (suppression of II-1 alpha and II-6), the improved benefit-risk ratio of PC compared to conventional glucocorticoids does not result only from distinct drug metabolism in the skin but also from a specific influence on the cytokine network.
通过评估局部用糖皮质激素泼尼松卡酯(PC)、其代谢产物泼尼松龙17 - 碳酸乙酯(PEC)和泼尼松龙(PD)、倍他米松17 - 戊酸酯(BMV)、倍他米松(BM)及地索奈德(DM)对表皮和真皮细胞的作用,对其进行药效学特征分析。总结药代动力学和药效学研究,可能解释泼尼松卡酯改善的效益风险比。
使用分离的包皮角质形成细胞研究对表皮炎症过程的影响,使用相同来源的真皮成纤维细胞研究糖皮质激素的抗增殖活性。通过酶联免疫吸附测定法(ELISA)检测白细胞介素,通过核糖核酸酶保护测定法在mRNA水平上研究对白细胞介素 - 1α(IL - 1α)产生的影响。通过3H胸苷掺入评估增殖情况,通过高效液相色谱/紫外吸收法评估生物降解情况。通过MTT测定法控制细胞活力。
在角质形成细胞中,肿瘤坏死因子α(TNFα)诱导炎症,导致IL - 1α合成增加。PC和BMV对该细胞因子的抑制作用尤为明显,而PEC、PD、DM和BM的作用较弱(p≤0.05)。然而,由于双酯PC在角质形成细胞中迅速降解,因此进行了IL - 1α mRNA的核糖核酸酶保护测定,允许短时间孵育,从而将生物降解作用降至最低。与先前的实验一致,证实了天然PC的抗炎效力。在成纤维细胞中,IL - 1α和IL - 6的合成分别表明增殖和炎症。PC仅在较小程度上抑制成纤维细胞中IL - 1α和IL - 6的产生,而传统糖皮质激素和PEC则使其显著降低(p≤0.05)。通过3H胸苷掺入测定,PC对成纤维细胞增殖的影响较小,这也反映了其较小的不良作用。BM、PEC尤其是BMV观察到更明显的抗增殖特征。
将角质形成细胞中的抗炎作用(抑制IL - 1α)与成纤维细胞中的抗增殖作用(抑制IL - 1α和IL - 6)相关联,与传统糖皮质激素相比,PC改善的效益风险比不仅源于皮肤中独特的药物代谢,还源于对细胞因子网络的特定影响。